Document Detail


The impact of the CYP2C9 and VKORC1 polymorphisms on acenocoumarol dose requirements in a Romanian population.
MedLine Citation:
PMID:  23159639     Owner:  NLM     Status:  Publisher    
Abstract/OtherAbstract:
AIM: To investigate the genotype-phenotype correlation in Romanian patients treated with acenocoumarol. MATERIAL AND METHODS: We studied 301 consecutive patients who required treatment with acenocoumarol, admitted within the Municipal Hospital of Cluj-Napoca and the Heart Institute "Niculae Stănciou" in Cluj-Napoca over a 3-year period. For each patient we recorded clinical parameters which could interfere with the achievement of stable therapeutic international normalized ratio (INR). We performed genetic analysis which consisted of genotyping the CYP2C9 gene and the VKORC1 gene. Patients were divided in three groups according to the acenocoumarol dose needed to reach a stable INR: the low dose group (≤7mg/week), the medium dose group (>7mg and <28mg/week) and the high acenocoumarol dose group (>28mg/week). RESULTS: We found that patients' age was significantly different between groups (p<0.001). No differences existed between groups regarding the pathologies which required anticoagulation therapy or the concomitant treatment. The following parameters increased the odds of receiving a low dose of acenocoumarol: patient's age over 65years (OR, 3.2; p=0.01; 95%CI: 1.24-8.25), the presence of the CYP2C9*3 allele (OR, 3.4; p=0.006; 95%CI: 1.41-8.34), and the GA or AA genotype of c.-1639G>A polymorphism of VKORC1 (OR, 6.5; p=0.01; 95%CI: 1.38-30.5; respectively OR, 11.6; p=0.003; 95%CI: 2.26-59.58). A high acenocoumarol dose was less likely to be administered to an elderly patient (OR, 0.24; p=0.001; 95%CI: 0.1-0.56) or to a patient with the GA or AA genotype (OR, 0.2; p<0.001; 95CI%: 0.09-0.45; respectively OR, 0.05; p=0.006; 95%CI: 0.007-0.43). CONCLUSION: The stable therapeutic dose of acenocoumarol is dependent of patient's age, the presence of the CYP2C9*3 allele and the c.-1639G>A polymorphism of VKORC1.
Authors:
Anca Dana Buzoianu; Florentina Claudia Militaru; Stefan Cristian Vesa; Adrian Pavel Trifa; Sorin Crişan
Related Documents :
11345029 - Comparative evaluation of the efficiency of various ukrain doses in the combined treatm...
1102569 - Metiapine: a double-blind comparison with chlorpromazine in acute schizophrenic patients.
17599019 - Constant magnetic field of 50 mt does not affect weight gain and blood glucose level in...
11329099 - Steady-state pharmacokinetics of high-dose diltiazem hydrochloride (cardizem cd) admini...
23814679 - Acute eosinophilic pneumonia leading to acute respiratory failure in a current systemic...
23369699 - Dose-dependent effect of statin therapy on circulating cxcl12 levels in patients with h...
12772369 - Test your knowledge. patient with a skin rash.
3711919 - An assessment of the possible protective effect of allopurinol in acute stroke.
11110009 - The efficacy of sertraline in panic disorder: combined results from two fixed-dose stud...
Publication Detail:
Type:  JOURNAL ARTICLE     Date:  2012-11-15
Journal Detail:
Title:  Blood cells, molecules & diseases     Volume:  -     ISSN:  1096-0961     ISO Abbreviation:  Blood Cells Mol. Dis.     Publication Date:  2012 Nov 
Date Detail:
Created Date:  2012-11-19     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  9509932     Medline TA:  Blood Cells Mol Dis     Country:  -    
Other Details:
Languages:  ENG     Pagination:  -     Citation Subset:  -    
Copyright Information:
Copyright © 2012 Elsevier Inc. All rights reserved.
Affiliation:
Department of Clinical Pharmacology, "Iuliu Haţieganu" University of Medicine and Pharmacy, 6th Pasteur Street, 400349, Cluj-Napoca, Cluj, Romania. Electronic address: abuzoianu@umfcluj.ro.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Anti-cancer versus cancer-promoting effects of the interleukin-17-producing T helper cells.
Next Document:  Mitochondrial dynamics in neurodegeneration.